Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.35M Buy
6,418
+323
+5% +$111K 0.22% 78
2026
Q1
$2.05M Sell
6,095
-66
-1% -$23.5K 0.2% 87
2025
Q4
$2.14M Buy
6,161
+296
+5% +$93.9K 0.24% 67
2025
Q3
$1.72M Buy
5,865
+793
+16% +$230K 0.16% 95
2025
Q2
$1.48M Buy
5,072
+245
+5% +$69.4K 0.12% 142
2025
Q1
$1.44M Buy
4,827
+3,862
+400% +$1.14M 0.13% 129
2024
Q4
$251K Buy
+965
New +$286K 0.03% 300

Other funds holding AMGN

Armis Advisers's AMGN Position: Q2 2026 in Review

Armis Advisers increased its Amgen (AMGN) stake by 5.3% in Q2 2026, buying an estimated $111K and bringing the position to 6,418 shares worth $2.35M. The position accounts for 0.22% of the portfolio, ranked #78.

Armis Advisers first reported a position in AMGN in Q4 2024 and has held it in 7 quarters since. 587 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Armis Advisers held 6,418 shares of Amgen worth $2.35M as of Q2 2026.
  • Armis Advisers bought 323 Amgen shares in Q2 2026, an estimated $111K.
  • Amgen made up 0.22% of Armis Advisers's portfolio in Q2 2026, its #78 holding.
  • Armis Advisers first reported a position in Amgen in Q4 2024 and has held it in 7 quarters since.
  • 587 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Armis Advisers's 13F filing for Q2 2026, filed 7 Jul 2026.